FINWIRES · TerminalLIVE
FINWIRES

BofA Securities Adjusts Price Target on Victoria's Secret & Co. to $95 From $68, Maintains Buy Rating

By

Victoria's Secret (VSXY) has an average rating of overweight and mean price target of $84.11, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $72.90, Change: $-7.16, Percent Change: -8.94%

Related Articles

Wire

BMO Capital Adjusts PT on Sherwin-Williams to $355 From $420, Maintains Outperform Rating

Sherwin-Williams (SHW) has an average rating of overweight and mean price target of $382.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $297.90, Change: $+4.89, Percent Change: +1.67%

$SHW
Wire

Amazon-Backed Anthropic's Mythos Accessible to European Union

Amazon (AMZN)-backed Anthropic's Mythos AI model is now accessible to the European Union Agency for Cybersecurity ahead of its release, the agency confirmed Wednesday in an emailed response to."Our priority now is to continue working with Anthropic to agree on the terms and conditions of the future access," the agency said.The agency added that a "new wave" of powerful AI tools is coming to the market and it is in discussions related to other "Frontier" AI models.Mythos is an AI model capable of identifying and exploiting vulnerabilities in operating systems and web browsers, Anthropic said in April.Price: $253.94, Change: $-2.58, Percent Change: -1.01%

$AMZN
Wire

MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study

MAIA Biotechnology (MAIA) said Wednesday it has received clearance from the US Food and Drug Administration to open enrollment for the expansion of the phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer.The firm said it obtained clearance of its updated investigational new drug application highlighting improved manufacturing capabilities, including new manufacturers and formulation.In addition to the US, the THIO-101 study is ongoing at 44 clinical sites in six countries, it added.The additional data from the expansion studies may further support a filing for an accelerated approval, MAIA said.Shares were up over 4% in morning trading.Price: $1.41, Change: $+0.06, Percent Change: +4.44%

$MAIA